Project Grant R01HL188930
- The National Heart, Lung, and Blood Institute awarded New York University $331,344 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on heart donor selection and utilization. The research addresses two primary barriers limiting U.S. heart transplant volume: insufficient evidence on which donor risk factors impact outcomes, and difficulty synthesizing clinical data during donor selection. The study will investigate the impact of specific...
- The National Institutes of Health National Heart Lung and Blood Institute awarded New York University $201,728 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research examining mechanisms contributing to functional recovery across the care cascade for respiratory failure. The research addresses how patient-level social determinants recorded at hospital admission, unit-level care processes during hospitalization, and community-level environmental...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $200,880 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop integrated host-microbe metagenomic sequencing methods for diagnosing and predicting complications in lung transplant recipients. The project will develop metagenomic classifiers from bronchoalveolar lavage fluid to more accurately diagnose lower respiratory tract infection in...
- The National Heart, Lung, and Blood Institute awarded the University of Florida $142,568 on June 1, 2026, through the Cardiovascular Diseases Research program (CFDA 93.837) to support career development of a mathematician-data scientist applying machine learning to predict early and chronic graft dysfunction after lung transplantation. The research integrates clinical and biological markers from donors and recipients to identify and validate predictors of primary graft dysfunction (PGD)...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,498 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on lung epithelial development and regeneration. The research aims to restore epithelial integrity and prevent end-stage lung diseases such as idiopathic pulmonary fibrosis by understanding how the lung epithelium develops in embryos and regenerates following injury....
- The National Heart, Lung, and Blood Institute awarded The Ohio State University $787,297 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 4, 2026. The award funds research into vascular dysfunction and lung allograft health, specifically investigating the mechanisms of primary graft dysfunction (PGD)—an ischemia-reperfusion injury that occurs in approximately 35 percent of lung transplants. The research examines how inflammasome-mediated pyroptosis and endothelial...
- The National Heart, Lung, and Blood Institute awarded Carnegie Mellon University $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to dissect lung spatial-biological niches in early fibrogenesis. The research project aims to spatially profile and recapitulate disease-specific microenvironments that drive early fibrogenesis in interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis. The work addresses a clinical need to elucidate...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $105,476 for a Project Grant (CFDA 93.837, Cardiovascular Diseases Research) on January 25, 2027. The award funds research addressing two critical shortcomings in the current donor heart allocation system. The project develops data-driven policy solutions to improve the prioritization of candidates with durable left ventricular assist devices (LVADs), which extend time on mechanical support but are...
- Federal Grant Award Summary New York University received a $272,226 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through August 31, 2027. The grant funds a secondary analysis research project that will deliver empirical evidence on how clinician and scheduling characteristics within intensive care unit (ICU) interprofessional teams impact patient outcomes for...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $795,464 to The Regents of the University of California, San Francisco on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into adaptive-like natural killer cells in pulmonary cytomegalovirus reactivation. The project investigates whether local cytomegalovirus-specific natural killer cell immune responses in the lungs potentiate...
The National Heart, Lung, and Blood Institute awarded New York University a Project Grant of $847,373 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The project will use national organ transplant registry data, including structured clinical data and unstructured narratives describing donor chest imaging findings, to improve evidence for lung offer decisions in transplantation. Large language models will be trained to extract structured data elements from unstructured text, capturing the presence and severity of lung abnormalities such as edema, pneumonia, and atelectasis. The research will quantify risk-adjusted associations between these newly structured data elements and post-transplant outcomes, including graft survival time, using statistical and causal inference methods. Machine learning methods will identify patterns and interaction effects in the data that suggest specific subgroups of patients who might benefit from particular donor lung profiles, addressing the substantial variability in clinical donor characteristics that currently complicates acceptance decisions and contributes to hundreds of patient deaths annually on the national lung waiting list. Work is performed at New York University School of Medicine in New York, New York. The period of performance extends from August 1, 2026, through April 30, 2031. The award is classified as a Project Grant, an assistance type reflecting the research funding structure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $847.4k | 7/23/26 |